Genmab | GEN - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Amarin USD 18.97M 1.03M 2025-12
Amgen USD 1.72B 134M 2026-06
argenx SE USD 417M 62M 2026-06
AstraZeneca USD 5.8B 735M 2026-06
Bayer EUR 3.96B 267M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Demant DKK 7.09B 1B 2026-06
Exelixis USD 147.63M 8.03M 2026-06
Fresenius Medical Care EUR 736.01M 12.99M 2026-06
Genmab DKK 205M 39M 2026-06
GlaxoSmithKline GBP 2.19B 75M 2026-06
GN Store Nord DKK 805M 42M 2026-06
GRIFOLS EUR 289M 8M 2026-06
Hikma Pharmaceutical USD 288M 149M 2025-12
Insmed USD 247.47M 208K 2026-06
Lakefront Biotherapeutics EUR 22.5M 13M 2026-06
Merck EUR 1.57B 49M 2026-06
Novartis USD 3.24B 101M 2026-06
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.63B 307M 2026-06
UCB EUR 1.47B 193M 2025-12